XML 49 R45.htm IDEA: XBRL DOCUMENT v2.4.0.8
ALLIANCES AND COLLABORATIONS (Pfizer) (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Dec. 31, 2012
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Net Sales $ 4,065 $ 3,736 $ 11,944 $ 13,430  
Deferred income 5,201   5,201   4,849
Eliquis [Member]
         
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Net Sales       1  
Pfizer [Member] | Eliquis [Member]
         
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Net Sales 41   75 1  
Profit sharing - Cost of products sold 19   35    
Cost reimbursements to/(from) collaboration partners - Commercialization expenses (4) (6) (21) (14)  
Cost reimbursements to/(from) collaboration partner - Research and development (6) (1) 3 10  
Maximum percentage of reimbursement for development costs from collaboration 60.00%   60.00%    
Minimum percentage of reimbursement for development costs from collaborations 50.00%   50.00%    
Pfizer [Member] | Eliquis [Member] | Upfront, milestone and other licensing payments [Member]
         
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total upfront, milestone and other licensing payments received 754   754    
Potential additional development and regulatory milestone receipts 130   130    
Amortization - Other (income)/expense (11) (10) (30) (29)  
Upfront, milestone and other licensing payments received 70   195    
Deferred income $ 562   $ 562   $ 397